- All sections
- C - Chemistrymetallurgy
- C12N - Microorganisms or enzymescompositions thereofpropagating, preserving, or maintaining microorganismsmutation or genetic engineeringculture media
- C12N 9/68 - Plasmin, i.e. fibrinolysin
Patent holdings for IPC class C12N 9/68
Total number of patents in this class: 82
10-year publication summary
4
|
8
|
6
|
5
|
4
|
8
|
6
|
6
|
3
|
3
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Modernatx, Inc. | 1258 |
9 |
Previpharma Consulting GmbH | 16 |
7 |
Monash University | 708 |
5 |
Gentium S.r.l. | 35 |
4 |
Kedrion Biopharma Inc. | 16 |
4 |
ThromboGenics NV | 13 |
4 |
ProMetic BioTherapeutics, Inc. | 12 |
4 |
Kedrion S.p.A. | 50 |
3 |
Talecris Biotherapeutics, Inc. | 13 |
3 |
Bioatla, Inc. | 106 |
3 |
Immunofyx | 3 |
3 |
Bausch & Lomb Incorporated | 1127 |
2 |
CSL Behring AG | 170 |
2 |
Grifols Therapeutics Inc. | 17 |
2 |
Talengen International Limited | 79 |
2 |
E. I. du Pont de Nemours and Company | 4127 |
1 |
Massachusetts Institute of Technology | 10002 |
1 |
Korea Institute of Science and Technology | 2113 |
1 |
AB Enzymes Oy | 73 |
1 |
Anhui New Star Pharmaceutical Development Co., Ltd. | 13 |
1 |
Other owners | 20 |